Acepodia's Dr. Sony Hsiao, CEO, and Dr. Mark Gilbert, SVP of R&D, join Business of Biotech for a discussion on the company's approach to dramatically reduce the cost of cell therapy development, manufacturing, and administration via its oNK, CAR, and ACC candidates. Listen now and subscribe so you never miss an episode.
By Anna Rose Welch, chief editor, Biosimilar Development
Though 2020 felt like an endless descent into Dante’s Nine Circles of Hell, I wanted to end the year as I typically do: with a column highlighting the most important and positive biosimilar developments from the past 12 months.
By D. Ecker and P. Seymour, BioProcess Technology Group, BDO USA
While capacity will increase over the next five years, demand for capacity — pandemic aside — will increase at a slightly faster rate. This increase will allow for some short-term loosening of capacity constraints, but after 2024, capacity tightening may occur.
This two-part article series explores the factors differentiating the Humira (adalimumab) biosimilar market from that of infliximab biosimilars, which could lead to stronger uptake of these products in the U.S. In Part 1, we focus on the unique competitive dynamics within the adalimumab biosimilar market.
It can be difficult to find industry-specific, easy-to-interpret, trustworthy market data. This ISR Reports e-book is chock full of free drug development and manufacturing facts, figures, and expert perspectives.